TIBET PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 13.95%
According to the Zhitong Finance APP, TIBET PHARMA disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 712 million yuan, a year-on-year increase of 1.12%; the net profit attributable to the parent company was 269 million yuan, a year-on-year decrease of 13.95%; the net profit excluding non-recurring gains and losses was 253 million yuan, a year-on-year increase of 7.90%. The basic earnings per share were 0.84 yuan
According to the Zhitong Finance APP, TIBET PHARMA (600211.SH) disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 712 million yuan, a year-on-year increase of 1.12%; the net profit attributable to the parent company was 269 million yuan, a year-on-year decrease of 13.95%; the net profit excluding non-recurring gains and losses was 253 million yuan, a year-on-year increase of 7.90%. The basic earnings per share were 0.84 yuan
